Log In
Print
BCIQ
Print
Print this Print this
 

tanezumab (PF-4383119, RN 624, RN-624) (formerly RI 624)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHumanized mAb against nerve growth factor (NGF)
Molecular Target Nerve growth factor (NGF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsTreat cancer pain; Treat chronic low back pain; Treat chronic low back pain and painful diabetic peripheral neuropathy (DPN); Treat chronic pain; Treat chronic pain due to interstitial cystitis; Treat chronic pain due to osteoarthritis (OA) of the knee; Treat osteoarthritis (OA); Treat pain due to osteoarthritis (OA) of the knee
Regulatory Designation

Partner

Eli Lilly and Co.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,750.0M

$200.0M

$1,550.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today